https://upstatecarolinancorp.org/active-surveillance-bleomycin-carboplatin-etoposide-or-cisplatin-in-treating-pediatric-and-adult-patients-with-germ-cell-tumors-agct1531/2024-02-12T11:58:06-05:00https://upstatecarolinancorp.org/regional-radiotherapy-in-biomarker-low-risk-node-positive-breast-cancer-cctg-ma-39/2024-02-12T11:58:32-05:00https://upstatecarolinancorp.org/nivolumab-and-ipilimumab-in-treating-patients-with-esophageal-and-gastroesophageal-junction-adenocarcinoma-undergoing-surgery-ea2174/2024-02-12T14:58:56-05:00https://upstatecarolinancorp.org/testing-maintenance-immunotherapy-versus-observation-in-patients-with-oropharynx-cancer-ea3161/2024-02-12T11:43:54-05:00https://upstatecarolinancorp.org/rituximab-with-or-without-stem-cell-transplant-in-treating-patients-with-minimal-residual-disease-negative-mantle-cell-lymphoma-in-first-complete-remission-ea4151/2020-12-08T15:40:36-05:00https://upstatecarolinancorp.org/the-national-myelodysplastic-syndromes-mds-study-nhlbi-mds/2024-02-12T11:44:21-05:00https://upstatecarolinancorp.org/lungmap-a-master-screening-protocol-for-previously-treated-non-small-cell-lung-cancer-screening-study/2024-03-21T14:29:19-04:00https://upstatecarolinancorp.org/solid-tumors-rare-tumor-types-s1609/2023-05-03T13:20:31-04:00https://upstatecarolinancorp.org/all-disease-sites-health-disparities-dcp-001/2024-02-12T12:06:48-05:00https://upstatecarolinancorp.org/ibrutinib-before-and-after-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-a051301/2022-04-13T12:30:56-04:00https://upstatecarolinancorp.org/adenoma-and-second-primary-prevention-trial-s0820/2024-03-21T14:02:11-04:00https://upstatecarolinancorp.org/myopenia-and-mechanisms-of-chemotherapy-toxicity-in-older-adults-with-colorectal-cancer-wf1806/2024-02-12T11:55:11-05:00https://upstatecarolinancorp.org/randomized-phase-ii-iii-trial-of-surgery-and-postoperative-radiation-delivered-with-concurrent-cisplatin-versus-docetaxel-versus-docetaxel-and-cetuximab-for-high-risk-squamous-cell-cancer-of-the-hea/2024-02-12T11:51:38-05:00https://upstatecarolinancorp.org/integration-of-immunotherapy-into-adjuvant-therapy-for-resected-nsclc-alchemist-chemo-io-a081801/2024-02-12T11:57:34-05:00https://upstatecarolinancorp.org/testing-the-use-of-combination-therapy-in-adult-patients-with-newly-diagnosed-multiple-myeloma-the-equate-trial-eaa181/2022-04-18T11:44:05-04:00https://upstatecarolinancorp.org/testing-the-addition-of-nivolumab-to-chemotherapy-for-patients-with-metastatic-anal-cancer-ea2176/2024-02-12T11:43:12-05:00https://upstatecarolinancorp.org/a-phase-ii-iii-trial-of-nivolumab-ipilimumab-and-gm-csf-in-patients-with-advanced-melanoma-ea6141/2021-07-07T14:14:38-04:00https://upstatecarolinancorp.org/testing-the-addition-of-radiation-therapy-to-the-usual-immune-therapy-treatment-atezolizumab-for-extensive-stage-small-cell-lung-cancer-the-raptor-trial-nrg-lu-007/2024-02-12T12:00:21-05:00https://upstatecarolinancorp.org/a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-nrg-cc008-sorock/2024-02-12T11:51:10-05:00https://upstatecarolinancorp.org/testing-cc-486-oral-azacitidine-plus-the-standard-drug-therapy-in-patients-75-years-or-older-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-s1918/2024-02-12T11:46:14-05:00https://upstatecarolinancorp.org/testing-the-application-of-mepitel-film-during-radiation-therapy-to-reduce-radiation-related-redness-and-peeling-in-breast-cancer-patients-following-mastectomy-a221803-2/2024-03-13T10:50:09-04:00https://upstatecarolinancorp.org/disparities-in-results-of-immune-checkpoint-inhibitor-treatment-direct-a-prospective-cohort-study-of-cancer-survivors-treated-with-anti-pd-1-antipd-l1-immunotherapy-in-a-community-oncology-setting/2024-03-11T16:12:53-04:00https://upstatecarolinancorp.org/high-dose-vitamin-d-supplementation-for-adt-induced-bone-loss-in-older-prostate-cancer-patients-urcc-22053/2024-02-12T11:40:34-05:00https://upstatecarolinancorp.org/a-randomized-trial-of-levocarnitine-prophylaxis-to-prevent-asparaginase-associated-hepatotoxicity-in-adolescents-and-young-adults-receiving-acute-lymphoblastic-leukemia-therapy-accl1931/2024-02-12T11:40:03-05:00https://upstatecarolinancorp.org/a-randomized-trial-of-levocarnitine-prophylaxis-to-prevent-asparaginase-associated-hepatotoxicity-in-adolescents-and-young-adults-receiving-acute-lymphoblastic-leukemia-therapy-accl1931-2/2024-02-12T12:11:38-05:00https://upstatecarolinancorp.org/a-randomized-phase-ii-study-of-inc280-capmatinib-plus-osimertinib-with-or-without-ramucirumab-in-participants-with-egfr-mutant-met-amplified-stage-iv-or-recurrent-non-small-cell-lung-cancer-s1900/2024-02-12T11:41:14-05:00https://upstatecarolinancorp.org/pragmatica-lung-a-prospective-randomized-study-of-ramucirumab-ly3009806-nsc-749128-plus-pembrolizumab-mk-3475-nsc-776864-versus-standard-of-care-for-participants-previously-treated-with-immunot-3/2023-09-11T10:00:34-04:00https://upstatecarolinancorp.org/pragmatica-lung-a-prospective-randomized-study-of-ramucirumab-ly3009806-nsc-749128-plus-pembrolizumab-mk-3475-nsc-776864-versus-standard-of-care-for-participants-previously-treated-with-immunot-4/2025-02-27T15:08:54-05:00https://upstatecarolinancorp.org/hypofractionated-radiotherapy-vs-single-fraction-radiosurgery-for-brain-metastasis-patients-on-immunotherapy-hypogryphe-wf-2201-2/2024-02-12T11:45:49-05:00https://upstatecarolinancorp.org/hypofractionated-radiotherapy-vs-single-fraction-radiosurgery-for-brain-metastasis-patients-on-immunotherapy-hypogryphe-wf-2201-3/2024-02-12T11:54:11-05:00https://upstatecarolinancorp.org/a-randomized-phase-3-trial-of-vinorelbine-dactinomycin-and-cyclophosphamide-vino-ac-plus-maintenance-chemotherapy-with-vinorelbine-and-oral-cyclophosphamide-vino-cpo-vs-vincristine-dactinomycin/2024-02-12T11:37:36-05:00https://upstatecarolinancorp.org/high-dose-vitamin-d-supplementation-for-adt-induced-bone-loss-in-older-prostate-cancer-patients-urcc-22053-2/2024-05-03T12:46:48-04:00https://upstatecarolinancorp.org/cognitive-training-for-cancer-related-cognitive-impairment-in-breast-cancer-survivors-a-multi-center-randomized-double-blinded-controlled-trial-nrg-cc011/2024-06-07T12:28:10-04:00https://upstatecarolinancorp.org/colon-adjuvant-chemotherapy-based-on-evaluation-of-residual-disease-circulate-us-nrg-gi008/2024-06-27T11:55:52-04:00https://upstatecarolinancorp.org/evaluating-the-addition-of-adjuvant-chemotherapy-to-ovarian-function-suppression-plus-endocrine-therapy-in-premenopausal-patients-with-pn0-1-er-positive-her2-negative-breast-cancer-and-an-oncotype-re/2026-03-26T15:59:51-04:00https://upstatecarolinancorp.org/comparing-telephone-symptom-monitoring-interventions-for-managing-symptoms-and-psychological-distress-during-oral-anti-cancer-treatment-nrg-cc012cd/2024-08-12T12:04:52-04:00https://upstatecarolinancorp.org/the-phase-iii-high-five-trial-five-fraction-radiation-for-high-risk-prostate-cancer-nrg-gu013/2024-08-29T14:58:28-04:00https://upstatecarolinancorp.org/phase-iii-prospective-randomized-trial-of-primary-lung-tumor-stereotactic-body-radiation-therapy-followed-by-concurrent-mediastinal-chemoradiation-for-locally-advanced-non-small-cell-lung-cancer-nrg/2024-08-29T15:51:13-04:00https://upstatecarolinancorp.org/longitudinal-observational-trial-to-uncover-subtypes-of-cancer-cachexia-urcc-22063/2025-07-14T13:33:13-04:00https://upstatecarolinancorp.org/improving-medication-adherence-in-metastatic-breast-cancer-using-a-connected-customized-treatment-platform-concurxp-eaq221cd/2024-11-04T16:11:24-05:00https://upstatecarolinancorp.org/complementary-options-for-symptom-management-in-cancer-cosmic-assessing-benefits-and-harms-of-cannabis-and-cannabinoid-use-among-a-cohort-of-cancer-patients-treated-in-community-oncology-clinics-w/2025-05-29T14:35:08-04:00https://upstatecarolinancorp.org/molecular-analysis-for-combination-therapy-choice-combomatch-eay191/2025-07-01T15:57:56-04:00https://upstatecarolinancorp.org/molecular-analysis-for-combination-therapy-choice-combomatch-eay191-2/2025-07-01T15:57:41-04:00https://upstatecarolinancorp.org/phase-iii-randomized-trial-of-standard-systemic-therapy-sst-versus-standard-systemic-therapy-plus-definitive-treatment-surgery-or-radiation-of-the-primary-tumor-in-metastatic-prostate-cancer-s180/2025-07-01T16:07:00-04:00https://upstatecarolinancorp.org/a-phase-iii-trial-of-one-vs-two-years-of-maintenance-olaparib-with-or-without-bevacizumab-in-patients-with-brca1-2-mutated-or-homologous-recombination-deficient-hrd-ovarian-cancer-following-resp/2025-09-09T10:30:57-04:00https://upstatecarolinancorp.org/a-feasibility-and-randomized-phase-2-3-study-of-the-vegfr2-met-inhibitor-cabozantinib-in-combination-with-cytotoxic-chemotherapy-for-newly-diagnosed-osteosarcoma-aost2032/2025-09-15T13:24:53-04:00https://upstatecarolinancorp.org/building-capacity-within-the-ncorp-network-through-an-education-and-mentorship-intervention-for-advanced-practice-providers-wf-2403/2025-10-08T12:42:33-04:00